sium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) in long-QT syndrome. 7 We previously showed that sustained β-adrenergic stimulation decreases I Ks density in the guinea pig, 8 but the underlying molecular basis remains poorly understood. β-Adrenergic stimulation causes cardiac remodeling via cAMP, classically mediated by protein kinase A (PKA); however, the novel protein family, exchange protein directly activated by cAMP (Epac), has been shown to mediate β-adrenoceptor actions. 9, 10 Little is known about the involvement of Epac in cardiac remodeling, particularly at the electrophysiological level. The present study aimed to clarify the molecular mechanisms underlying β-adrenergic downregulation of I Ks , with a particular focus on the potential role of Epac.
Methods
For detailed methods description, see the Online Data Supplement.
Cardiomyocyte Isolation
Guinea pigs were injected with heparin (1.0 U/kg) and euthanized by stunning-induced areflexic coma followed by cardiac excision. Hearts were retrogradely perfused with 200 μmol/L Ca 2+ -containing Tyrode solution. When clear, the perfusate was changed to Ca 2+ -free Tyrode solution and digested with 280 U/mg collagenase type II. Cells were obtained by trituration and stored in Kraftbrühe solution.
Cell Culture and Treatment
Cardiomyocytes were reintroduced to Ca 2+ by stepwise addition of cell culture medium. Cells were plated and maintained at 37°C in a humidified, 5% CO 2 -enriched atmosphere. After 2 hours, fresh medium was added and supplemented with 1-μmol/L isoproterenol in drug treatment groups. Cells were kept in culture for an additional 30 hours. In some experiments, 1-[2-((3-carbamoyl-4-hydroxy) phenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanol dihydrochloride (CGP-20712A); (±)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride (ICI-118551); 8-Br-cAMP; 7β-acetoxy-8,13-epoxy-1α,6β,9α-trihydroxylabd-14-en-11-one (forskolin); 8-pCPT-2′-O-Me-cAMP (8-pCPT); inhibitor of nuclear factor of activated T cell (NFAT)-calcineurin association-6 (NFAT6); cyclosporine; 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetate acetoxymethyl ester (BAPTA)-AM; myristoylated protein kinase A inhibitor peptide (PKI); U-73122; N- [2- [N-(4-chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-(2-hydroxyethyl)-4-methoxybenzenesulfonamide phosphate salt (KN93); KN92; or N-[4-[2(R)-amino-3-mercaptopropyl]amino-2-(1naphthalenyl)benzoyl]-l-leucine methyl ester trifluoroacetate salt (GGTI) were added to cultured cardiomyocytes along with isoproterenol (1 μmol/L). In other experiments, shRNA in an adenoviral vector, produced based on previously described methods, 11, 12 was used to knockdown Epac1 (Online Figure I) . In all experiments studying effects of blockers on isoproterenol action, cells from the same isolates were exposed in parallel to isoproterenol as an internal control. T-tubule distribution (with di-4-ANEPPS as a marker) and proteinsynthesis ([ 3 H]-leucine incorporation) were assessed in isolated cells as described in Methods in the Online Data Supplement.
Electrophysiology

Cell Culture
After 30 hours of exposure to interventions, cardiomyocytes were washed with Tyrode solution before study.
Freshly Isolated Cells After In Vivo Treatment
Cells were studied within 8 hours of isolation. Tight-seal whole-cell patch-clamp technique was used to record currents in voltage-clamp mode. APs were recorded with perforated patch current clamp. All experiments were performed at 36±1°C. For detailed electrophysiological methods, see Methods in the Online Data Supplement. Cell capacitance was 104±4 pF for control and 106±4 pF for isoproterenol-treated cells in culture; 199±11pF for in vivo vehiclecontrol and 252±16 pF isoproterenol-treated groups (P<0.05); 146±9 pF for vehicle-control and 180±11 pF for sp-8-pCPT-treated animals (P<0.05) for cells isolated from in vivo-treated animals.
Immunoblots and Immunochemistry
Membrane protein was denatured and fractionated on 8% SDS-PAGE and then transferred electrophoretically to immobilon-P polyvinylidene fluoride membranes. Membranes were incubated with primary antibodies overnight and then exposed to secondary antibodies. All results were normalized to GAPDH immunoblots. Immunochemistry was used to quantify membrane expression of KCNE1 protein and nuclear translocation of NFAT.
Real-Time Polymerase Chain Reaction
For RNA isolation and quantitative PCR methods, see Methods in the Online Data Supplement. Gene expression levels were normalized to the geometric average of multiple reference genes. 13
In Vivo Models
Guinea pigs received daily intraperitoneal injections of isoproterenol or vehicle. Isoproterenol was injected at an initial dose of 50 μg/kg per day. The dose was increased 100 μg/kg per day every week for 13 weeks. To produce in vivo Epac activation, sp-8-pCPT was administered via osmotic minipump (16 μg/d) for 6 weeks; vehicle-filled minipumps were used for parallel control animals. Echocardiography was used to assess cardiac function changes 14 
Results
Sustained β-Adrenergic Stimulation Decreases I Ks
We first established the stability of the guinea pig cell culture system in vitro (Online Figure II) . I Ks density, as well as protein expression of the underlying KCNQ1 and KCNE1 subunits, was stable in the absence of isoproterenol. Isoproterenol treatment increased cell area by ≈50% (Online Figure IIIA) , did not affect cell capacitance (Online Figure IIIB) , and increased leucine incorporation (Online Figure IIIC) . T-tubule density decreased in culture, with significantly greater decreases in isoproterenoltreated cells versus parallel controls (Online Figure IIID and IIIE), potentially accounting for unchanged capacitance in isoproterenol-treated cells, despite increased cell size. I Ks recordings from control and isoproterenol (1 μmol/L)-treated cells are shown in Figure 1A and 1B. Figure 1C and 1D shows overall current density/voltage relations, indicating a significant decrease (by ≈60%) in isoproterenol-treated cells. Current densities normalized to maximum 
Involvement of β 1 -Adrenoceptors and cAMP Signaling
Cells incubated with isoproterenol and highly selective β1 (CGP-20712A) or β2 (ICI-118551) antagonists were compared with parallel control and isoproterenol-alone groups. Figure 2A shows representative I Ks recordings. Corresponding current density/voltage relationships ( Figure 2B ) indicate that concomitant treatment with the β 1 -blocker CGP-20712A abolished the isoproterenol effect. The β 2 -blocker ICI-118551 failed to alter isoproterenol action, confirming that the isoproterenol effect is mediated through β 1 -adrenergic receptors.
After β 1 -adrenoceptor activation, the trimeric G-protein complex releases G αs , which activates adenylyl cyclase, increasing intracellular cAMP levels. 15 Sustained exposure to the cell-permeable cAMP agonist 8-bromo-cAMP reduced I Ks ( Figure 2C ), mimicking isoproterenol effects ( Figure 2D ). Similar changes were observed with forskolin, which increases intracellular cAMP levels by directly activating adenylyl cyclase ( Figure 2E and 2F). Acute I Ks enhancement caused by β-adrenergic stimulation is mediated by PKA activation/phosphorylation of KCNQ1 on Ser-27. 16 To evaluate the role of PKA in I Ks downregulation, cardiomyocytes were exposed for 30 hours to isoproterenol in the presence of the N-myristoylated (cell permeable) form of the peptide PKA-inhibitor PKI (1 μmol/L). PKI did not suppress isoproterenol-induced I Ks downregulation ( Figure 2G and 2H). In contrast, PKI blunted I Ks enhancement resulting from acute isoproterenol exposure (Online Figure VA and VB), indicating that the persistent chronic-isoproterenol effect in the presence of PKI is not because of inactivity of PKI. In addition, chronic treatment of cells with 8-Br-cAMP plus PKI suppressed I Ks , further excluding the involvement of PKA ( Figure 2E and 2F).
Involvement of Epac
To assess the involvement of Epac, we treated cardiomyocytes with 6-μmol/L 8-pCPT-2′-O-Me-cAMP (8-pCPT), a highly selective Epac activator. 17 Sustained Epac activation with 8-pCPT reduced I Ks densities to values comparable with those in a parallel isoproterenol-treated group ( Figure 3A ; eg, at +50 mV, from 3.3±0.4 pA/pF in control to 1.7±0.2 pA/pF in isoproterenol and 1.4±0.2 pA/pF in . Figure 3A and 3B shows that Epac stimulation can mimic the effect of isoproterenol, but to establish the role of Epac as a mediator of isoproterenol-induced I Ks downregulation, it is necessary to assess the effects of Epac inhibition on isoproterenol action. In the absence of a specific pharmacological inhibitor, we turned to genetic knockdown. Two isoforms of Epac (Epac1 and Epac2) are encoded by distinct genes (RAPGEF3 and RAPGEF4). 18 Epac1 is highly expressed in the heart, kidneys, ovaries, and thyroid glands, whereas Epac2 is predominant in the brain and pituitary. 19 Furthermore, isoproterenol treatment enhanced the expression of Epac1 in our in vitro system (Online Figure VIA) and not that of Epac2 (Online Figure  VIB) and increased the Epac1/2 expression ratio (Online Figure VIC ). Based on these data, we decided to target Epac1 and designed a specific shRNA (Online Figure I) , along with a scrambled control sequence, each inserted in bicistronic adenoviral delivery vectors incorporating green fluorescent protein. Incubation with the Epac1 knockdown-virus attenuated Epac1 expression after isoproterenol exposure (Online Figure  VIIA) , whereas Epac2 expression was unaffected (Online Figure VIIB) . The scrambled-virus did not alter Epac expression in the presence of isoproterenol (Online Figure VIIA) , and isoproterenol significantly increased Epac1 expression in the presence of scrambled-virus versus scrambled-virus incubation alone (Online Figure VIIIA) . Figure 3C shows representative I Ks recordings in cells treated with isoproterenol in the presence of the scrambled-control virus, knockdown-virus, and virus noninfected control, respectively. Epac1 knockdown suppressed isoproterenol-induced downregulation of I Ks , as compared with isoproterenol-alone and scrambled sequence ( Figure 3D and 3E). These data are strong evidence for a central role of Epac1 in isoproterenol-induced I Ks downregulation.
Role of Ca 2+ /Calcineurin/NFAT
Epac action is commonly transduced by increased intracellular Ca 2+ levels. 20 To determine the role of cell Ca 2+ in mediating effects of Epac in our system, we used a cell-permeable calcium chelator (BAPTA-AM, 10-μmol/L). Cardiomyocytes incubated with isoproterenol and BAPTA-AM did not show a reduction in I Ks current density on isoproterenol exposure ( Figure 4A ), whereas cells from the same isolates exposed to isoproterenol showed typical I Ks suppression.
We then turned our attention to potential downstream Ca 2+dependent mediators of Epac action. Calcineurin is a Ca 2+activated phosphatase that is known to mediate Epac-induced cardiac hypertrophy. 10 To assess the role of calcineurin, cardiomyocytes were treated with the calcineurin blocker cyclosporine A (0.8 μmol/L). Cyclosporine prevented the isoproterenol-induced downregulation of I Ks ( Figure 4B) . A major mediator of calcineurin action is the nuclear factor of activated T-lymphocytes, which is dephosphorylated by calcineurin, allowing increased transport into the nucleus and enhanced transcription factor action. 21 Figure 5A shows enhanced nuclear localization of NFATc4 (red) and NFATc3 (green) following isoproterenol exposure. Overall nuclear localization was increased for both NFATc3 (by ≈61%; P<0.01) and NFATc4 (≈42%; P<0.05) by isoproterenol incubation (Figure 5B ). To assess the functional role of NFAT in I Ks downregulation, we treated cardiomyocytes with a cell-permeable NFAT blocker (inhibitor of NFAT-calcineurin association-6; 1-μmol/L), which prevented I Ks downregulation by isoproterenol ( Figure 5C and 5D). Epac1 knockdown suppressed β-adrenergically mediated translocation of NFATc3 and c4 into the nucleus, confirming NFAT translocation as an event downstream to isoproterenolinduced Epac activation (Online Figure IX) .
In Vivo Models
Chronic in vivo β-adrenergic stimulation increased left ventricular mass/body weight ratio, indicating cardiac hypertrophy (Online Table II ). Echocardiography showed significant impairments in left ventricular ejection fraction and fractional shortening (Online Table III ). Figure 1E and 1F shows representative I Ks recordings from control and isoproterenol-treated animals. I Ks density was significantly reduced, by ≈65% ( Figure 1G and 1H) . In vivo isoproterenol administration did not alter I Ks voltage dependence (Online Figure IVE and IVF) but significantly accelerated I Ks activation (Online Figure IVG and IVH), similar to the effect observed in vitro. Of note, in vivo isoproterenol administration did not cause detubulation (Online Figure IIIF and IIIG). AP duration was significantly increased in isoproterenol-treated animals ( Figure 1I and 1J) . The expression of both Epac1 and Epac2 mRNA was increased (Online Figure VID and VIE) , but the increase in Epac2 was larger than in Epac1, decreasing the Epac1/Epac2 expression ratio (Online Figure VIF) . In vivo isoproterenol also remodeled other ionic currents, reducing L-type calcium current (I CaL ) density by ≈45% and inward rectifier current (I K1 ) by ≈47% (Online Figure X) . In vivo administration of the Epac activator sp-8-pCPT decreased I Ks by ≈64%, reproducing the effect of isoproterenol ( Figure 3F and 3G) . AP duration was significantly prolonged in sp-8-pCPT-treated animals ( Figure 3H ). As was the case for isoproterenol, I CaL and I K1 were reduced (by ≈30% each) in sp-8-pCPT-treated animals (Online Figure XI) . 
Molecular Basis of Isoproterenol/Epac Effect on I Ks
To further address the mechanisms underlying I Ks downregulation, we assessed mRNA expression for the I Ks subunits KCNQ1 and KCNE1. KCNQ1 mRNA expression was not significantly altered ( Figure 5E ), but KCNE1 mRNA expression was clearly reduced, by ≈45% ( Figures 5F and 6A) . These results suggest KCNE1 as the downstream target of the Epac1-stimulated Ca 2+ /calcineurin/NFAT system. Numerous NFAT-binding sites are located on the 5′-upstream region of the guinea pig transcriptional start site for KCNE1, including 1 within 300 bp (Online Figure XII) . The NFAT blocker inhibitor of NFAT-calcineurin association-6 (INCA6) suppressed KCNE1 downregulation ( Figure 5F ), without altering KCNQ1 expression ( Figure 5E ), consistent with NFAT-mediated regulation. Representative KCNE1 immunoblots are shown, along with mean data, in Figure 6A . Isoproterenol incubation reduced KCNE1 protein expression significantly, by 56%. The protein expression changes were further confirmed via immunostaining ( Figure 6B ), which showed reduced membrane expression of KCNE1 protein (by ≈82%; P<0.01) in response to sustained in vitro isoproterenol exposure. Corresponding in vivo results are shown in Figure 6C and 6D. KCNE1 protein and mRNA expression were significantly decreased after in vivo isoproterenol administration ( Figure 6C ). Similar changes were seen with in vivo sp-8-pCPT infusion ( Figure 6D ).
The results above indicated an important role for Ca 2+ / calcineurin/NFAT signaling but do not exclude the involvement of other molecular pathways. Ras-related protein 1 (Rap1) is known to be activated after Epac activation. 18 Its potential role was assessed by incubating cells with GGTI (a Rap1 blocker). GGTI prevented isoproterenol-induced I Ks reduction (Online Figure XIIIA and XIIIB) . Phospholipase C (PLC) is another downstream effector of some Epac1 effects. 22 Concomitant treatment of cells with isoproterenol and U-73122 (a phospholipase C inhibitor) did not prevent isoproterenol-induced reductions in I Ks density (Online Figure  XIIIC and XIIID). Ca 2+ /calmodulin-dependent kinase type II (CaMKII) is known to be activated by β 1 -adrenergic stimulation. 23 Concomitant stimulation of cells with isoproterenol and KN93 (a CaMKII blocker) prevented reductions in I Ks density, whereas the inactive congener KN92 was ineffective (Online Figure XIIIE and XIIIF) , indicating the necessity for intact CaMKII activity for the isoproterenol effect. In the absence of adrenergic stimulation, neither GGTI nor KN93 altered I Ks (Online Figure XIV ).
Discussion
In this study, we found that chronic β-adrenergic stimulation decreases I Ks density both in vitro and in vivo while downregulating KCNE1 subunits. Detailed characterization in vitro showed that this effect is mediated via Epac signaling through the Ca 2+ /calcineurin/NFAT pathway. A summary of our experimental observations and the mechanistic model they suggest is provided in Figure 7 .
Remodeling of Delayed-Rectifier K + Currents
The delayed-rectifier K + current system is crucial for cardiac repolarization in mammals. I Ks downregulation occurs in patients with terminal CHF 1 and in ventricular and atrial cells from different animal models. 3, [24] [25] [26] [27] [28] [29] [30] Animal models of hypertrophy also show reduced I Ks.
31 Atrioventricular blockinduced remodeling also decreases I Ks in ventricular cardiomyocytes. 32, 33 Less is known about the signal-transduction mechanisms that lead to I Ks downregulation and the underlying changes in I Ks subunits. Prior studies have provided discrepant results. Tsuji et al 24 showed a decrease in both KCNQ1 and KCNE1 subunits in rabbits with tachypacing-induced heart failure, with a corresponding change in the protein. However, other studies of tachypacing-induced CHF in dogs 6 and rabbits 30 did not show changes in KCNQ1 and KCNE1 mRNA or protein expression. Borlak et al 34 reported an increase in KCNQ1 and KCNE1 subunit mRNA in heart samples from humans with end-stage CHF. Some of the discrepancies may be because of differences in the severity and duration of CHF, as well as species and drug therapy conditions. The QT-interval prolongation associated with K + -channel downregulation is a significant predictor of sudden cardiac death in patients with CHF. 35 
Epac Signaling in Cardiac Remodeling
cAMP, the universal second messenger that is produced via adenylyl cyclase after β-receptor activation, plays an important role in cardiovascular physiology. Although PKA is the primary effector of cAMP, other more recently identified proteins, such as Epac, represent important signaling mechanisms downstream to cAMP. Here, we report that chronic in vitro stimulation of β 1 -adrenergic receptors activates Epac1, which decreases I Ks density independently of PKA. In vivo, isoproterenol administration increases Epac expression, and its effects are mimicked by an Epac agonist. Epac1 (RAPGEF3) mRNA is highly expressed in heart. 36 Myocardial Epac1 expression increases in rats with pressure-overload induced by aortic constriction and in rat ventricular cardiomyocytes treated with isoproterenol. 10 Epac1 and Epac2 are also upregulated in the hearts of mice subjected to chronic-isoproterenol infusion. 37 Epac1 expression is increased ≈2-fold in ventricular cardiomyocytes from patients with CHF, with no change in Epac2 expression. 10 Thus, cardiac Epac expression increases under cardiac-load and adrenergic-stimulation conditions that cause hypertrophy and remodeling. There is extensive evidence for a causative role of Epac in cardiac hypertrophy. 20 Little is known about the role of Epac in cardiac electrophysiology. Epac activation inhibits ATP-sensitive K + -channels in pancreatic β-cells 38 and Epac1 coimmunoprecipitates with SUR1, a subunit of the K ATP -channel. Exposure of rat chromaffin cells to 8-pCPT increases T-type Ca 2+ -current and Ca v 3.1-subunit expression. 39 Acute perfusion of rat and mouse cardiomyocytes with 8-pCPT does not affect L-type Ca 2+ current, 23, 40 but the Epac activator 8-4-(chlorophenylthio)-2'-O-methyladenosine-3',5'monophosphate (cpTOME) strongly enhances Ca 2+ -induced Ca 2+ release in mouse cardiomyocytes. 22 Acute Epac activation failed to induce any changes in AP duration in 2 studies 40, 41 ; however, a more recent investigation showed AP duration increases in rats after acute 8-CPT-acetoxymethyl-ester perfusion. 42 Epac activation increases Ca 2+ sparks via CaMKII phosphorylation of ryanodine receptors in rat cardiomyocytes. 40 A recent elegant study showed that in vivo infusion of an Epac activator to rats elicits a PKA-independent positive inotropic response, increases cardiomyocyte Ca 2+ transients, enhances sarcoplasmic reticulum Ca 2+ stores and Ca 2+ transients, and promotes Ca 2+ -dependent arrhythmic activity. 43 Inhibition of calcineurin or CaMKII prevented Epac-induced Ca 2+ responses.
The present study is the first to implicate Epac in I Ks remodeling. The Epac dependence of adrenergically induced I Ks downregulation was established by the ability of direct Epac activation to mimic adrenergic effects, the lack of change with PKA inhibition, and the suppression of adrenergic effects on I Ks and KCNE1 expression when Epac was knocked down. Signaling was Ca 2+ dependent (as evidenced by the effect of BAPTA) and required intact calcineurin action (shown by suppression with cyclosporine A). NFAT translocation was a central event: blockade of calcineurin-induced NFAT dephosphorylation with INCA6 prevented I Ks and KCNE1 downregulation, and the suppression of isoproterenol-induced I Ks downregulation by Epac knockdown was accompanied by the prevention of NFAT translocation to the nucleus. The signaling system that we uncovered is consistent with prior studies of Epac effects in the heart. Calcineurin activity is increased in cells treated with 8-pCPT, 10 and Epac activation is known to significantly increase NFAT nuclear translocation, 44 which is important for the induction of cardiac hypertrophy.
Relationship to Other Signaling Systems in K + Channel Remodeling
Rossow et al 45 have shown spatial heterogeneity of NFATc3-dependent I to downregulation, causing a loss of the normal transmural gradient in mouse ventricular cardiomyocytes after chronic in vivo isoproterenol infusion. β-Adrenergic stimulation increased intracellular Ca 2+ , calcineurin, and NFAT activity, which reduced Kv4.2 expression and I to density. 45 The upstream pathway was not identified. In mice with myocardial infarction, downregulation of I to and I Kslow1,2 was prevented by calcineurin inhibition or NFATc3 knockout. 46 Although calcineurin/NFAT signaling suppresses I to transcription in most studies, 47, 48 I to upregulation occurs in neonatal rat cardiomyocytes. 49 Cav1.2 is downregulated via the same pathway in canine cardiomyocytes. 50 NFAT is an important downstream mediator of responses to changes in intracellular Ca 2+51 ; our data are the first showing a role in downregulating delayed-rectifier K + -currents.
We also identified the involvement of other signaling molecules, such as CaMKII and Rap1, in I Ks regulation. Previous studies have identified a role for CaMKII in I to downregulation in tachycardia remodeling of canine ventricular cardiomyocytes. 48 Interestingly, in that work, like the present study, the primary signaling system involved was the Ca 2+ /calcineurin/ NFAT system, but intact CaMKII function was necessary for K + current downregulation. CaMKII activation also suppresses delayed-rectifier K + currents in neurons. 52 Transgenic CaMKIIδc overexpression reduces Kir2.1 expression and I K1 in mice. 53 CaMKII-expression is increased in calcineurin-transgenic mice; CaMKII-inhibitory drugs improve left ventricular function and prevent arrhythmias. 54 Less is known about the role of Rap1 in cardiac electrophysiology. Rap1, along with phospholipase C, participates in Ca 2+ -induced Ca 2+ -release after β-adrenergic stimulation and Epac activation. 22 It is possible that CaMKII and Rap1 contribute to Ca 2+ liberation, which we found was essential for I Ks downregulation. Prior studies have demonstrated a role for Rap1 and CaMKII in Epac-induced increases of murine Ca 2+ -induced Ca 2+ release, although intact phospholipase C was also needed. 22 Additional work will be needed to clarify the detailed molecular signaling associated with these molecules.
Novel Findings and Potential Significance
Our study is the first to define the mechanisms underlying I Ks downregulation induced by chronic β-adrenergic stimulation. It is also the first to show a central role of Epac signaling in the control of K + channel expression. Our findings may be relevant to the prevention of malignant arrhythmias in a variety of contexts. Sympatho-adrenergic activation is an important contributor to arrhythmic risk in patients with CHF, 4 as well as in animal models. 55 It may become possible to target Epac-mediated electric remodeling to prevent potentially lethal arrhythmic events. β-Adrenoceptor blockers are the mainstay of therapy to prevent arrhythmic events in long-QT syndrome patients. 56 Their protective action is reasonably attributed to the suppression of acute electrophysiological effects of adrenergic stimulation; however, they may also act to maintain repolarization reserve that might otherwise be suppressed by downregulation of I Ks through chronically elevated background adrenergic tone. The Epac system was described relatively recently, 18 and our knowledge about its role in cardiac pathophysiology is rather limited. 57 Our study is the first to implicate Epac in cardiac ion-channel remodeling and to detail the associated signaling pathway. More work is needed to establish the role of Epac signaling in other aspects of cardiac electric remodeling.
One potentially interesting and novel aspect of the remodeling we observed was a change in the kinetics of I Ks with chronic exposure to isoproterenol or agents that mimicked its signaling like 8-bromo-cAMP and 8-pCPT. The KCNE1 subunit is known to contribute importantly to the formation of I Ks channels, slowing activation and enhancing current density. 58 The kinetic changes that we observed may therefore be caused by selective downregulation of KCNE1, with consequent changes in KCNE1:KCNQ1 stoichiometry.
Potential Limitations
We used an in vitro primary culture system of adult ventricular cardiomyocytes, with an animal system that, unlike mouse and rat models, has important delayed-rectifier K + currents of the type important for human cardiac repolarization. The use of this in vitro system allowed the exploration of detailed mechanisms with probes not readily applicable in vivo. Changes in cardiomyocyte properties over time in culture are a potential problem, but we established the stability of I Ks density and associated subunits in culture. In addition, the density of I Ks sometimes varied among different sets of cells. We therefore included internal controls (generally, cells cultured in vehicle and isoproterenol) for each set of experiments. Thus, each data set shown consists of simultaneously cultured/studied cells from each isolate. There are important differences in I Ks properties among species. 59, 60 Caution is therefore needed in extrapolating our results to other species, especially humans.
We observed cellular hypertrophy after chronic-isoproterenol exposure in terms of increased cell dimensions, but not capacitance. The discrepancy is likely related to the detubulation that occurs in cultured cardiomyocytes, 61 which was exaggerated by isoproterenol and reduces the effective cell membrane surface area (Online Figure III) . Chronic in vivo isoproterenol stimulation produced similar changes in I Ks and KCNE1 expression to those seen with in vitro treatment, despite no evidence of detubulation and a significant increase in cell capacitance. Interestingly, in vivo Epac administration reproduced the I Ks remodeling effects of isoproterenol.
The electrophysiological consequences of background adrenergic tone in vivo will reflect the chronic ion-channel remodeling effects plus any additional changes because of ongoing (acute) adrenergic signaling. The ion-channel remodeling we observed affected adrenergically enhanced outward K + current (60% decrease in I Ks ) more than inward Ca 2+ current (45% reduction). Thus, any acute adrenergic effects would be expected to increase inward current more than outward and to further delay repolarization. Additional work is clearly needed to define the mechanisms of adrenergic regulation of ion channels other than I Ks , to determine the systems effects of chronically elevated adrenergic tone in vivo and to assess their specific role in disease-state paradigms like CHF.
We performed in vivo experiments to determine whether the phenomena we observed under cell-culture conditions in vitro also pertain to the effects of sustained β-adrenergic stimulation in vivo. We based our in vivo study conditions for isoproterenol on previous studies in the guinea pig, which showed that significant changes in cardiac structure/function/electrophysiology required 3 months of incremental intraperitoneal therapy. 62 We based the Epac regimen on prior studies in rats, which used continuous infusion for 4 weeks, 63 but we increased the duration of therapy to 6 weeks, the maximum duration possible with our osmotic minipumps, because of anticipated potential species differences. In view of differences in exposure period, dose, etc, the different series we performed can only be compared qualitatively: in vivo isoproterenol and sp-8-pCPT produced similar effects to each other, with changes consistent with our in vitro observations. The in vitro model allowed us to perform extensive detailed mechanistic studies that could not be practically executed in vivo, whereas the in vivo studies allowed us to confirm that the phenomena we observed in vitro are applicable to in vivo conditions. We used sp-8-pCPT as an Epac-selective agonist, as have many prior studies, 10, 17, 20, 22, 36, 38, [40] [41] [42] [43] [44] but sp-8-pCPT products can have effects on other signaling systems. 64 We confirmed the role of Epac signaling in vitro with adenoviral-mediated knockdown; however, we were unable to apply gene knockdown in vivo; this limitation should be considered in interpreting our results.
